Sarcoidosis is a systemic granulomatous disease of unknown etiology and pathogenesis, in which there is an increased risk of pulmonary thromboembolism (PE). This manuscript presents two clinical cases of PE in patients with sarcoidosis.
Patients with sarcoidosis are at risk of developing PE. All patients with sarcoidosis and impaired respiratory function, especially those with severe and chronic disease, should be closely monitored for the presence of PE due to the potentially fatal nature of the complication.
Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost 2007;5:692-9.
Cushman M, Tsai AW, White RH, et al. Deep venous thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25.
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14.
Silvarino R, Danza A, Merola V, et al. Venous thromboembolic disease in systemic autoimmune diseases: An association to keep in mind. Autoimmune Rev 2012;12:289-94.
Crawshaw AP, Wotton CJ, Yeates DGR, Goldacre MJ, Ho L-P. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011;66(5):447–8.
Ungprasert P, Crowson CS, Matteson E. Association of sarcoidosis with increased risk of VTE. A Population-Based Study, 1976 to 2013. Chest 2017;151(2):425-30.
Marc K, Bourkadi J, Benamor J, Iraqi G. Thoracic venous thrombosis in the course of sarcoidosis. Rev Mal Respir 2008;25:105–6.
Nagareddy P, Smyth SS. Inflammation and thrombosis in cardiovascular disease. Curr Opin hematol 2013;20:457-63.
Kolluri N, Elwazir MY, Rosenbaum AN, et al. Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis on Frequency of Venous Thromboembolism. Am J Cardiol 2021;149:112-8.
Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010;30(1):5-6, 8-9.
Jezovnik MK, Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction. Int Angiol 2010;29:226-31.
Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res 2011;63(2):178-83.
Meduri GU, Annane D, Confalonieri M, et al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensiv Care Med 2020;46:2284–96.
Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011;305:391-9.
Ungprasert P, Srivali N, Wijarnpreecha K, Thongprayoon C. Sarcoidosis and risk of venous thromboembolism: A systematic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2015;32(3):182-7.
Goljan-Geremek A, Geremek M, Puscinska E, Sliwinski P. Venous thromboembolism and sarcoidosis: Co-incidence or coexistence? Cent-Eur J Immunol 2015;40:477–80.
